PHARMACOLOGY UPDATE

Apomorphine Hydrochloride Injection (Onapgo)

March 30, 2025

The U.S. Food and Drug Administration has approved apomorphine as a constant subcutaneous infusion for the treatment of advanced Parkinson’s disease with persistent motor fluctuations. It is the second subcutaneous infusion for this indication following foscarbidopa/foslevodopa (as Vyalev).

Issue Date: March 30, 2025

Table of Contents

Dr. Stephen Brunton, physician editor, reports he is on the speakers bureau for AstraZeneca, the advisory board for Novo Nordisk, the speakers bureau and advisory board for Abbott Diabetes, and is a stockholder with Paracrine. The relevant financial relationships listed for this individual have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements